Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  31.00 2.08% 1,522.50 1,525.50 1,526.50 1,532.00 1,498.00 1,499.50 1,830,983 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,874.2 560.2 51.7 29.8 13,332

Smith & Nephew Share Discussion Threads

Showing 776 to 800 of 925 messages
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
11/10/2017
10:11
stryker are the obvious home for it - not sure where they are at but recall they put in place a large buy back programme in 15 instead of bidding for sn. their balance sheet is very solid so they could easily make a juicy bid imo. lets see but funny how the ceo left abruptly....
edwardt
11/10/2017
09:10
Year's high.
steeplejack
11/10/2017
08:55
Elliott are renowned for shaking things up - the spat at BHP is illustrative of this.
edwardt
11/10/2017
08:14
Lets hope there might be something in it. Perennial bid candidate though - that's why I bought and hold. One day, Rodney.
broadwood
11/10/2017
08:11
FT reports this morning that the stock rose on news that Eliott Management had built a stake.Nothing more than that at the moment
steeplejack
11/10/2017
07:46
Elliot rumoured to have built a stake - can not see an rns to that effect - anyone know more?
edwardt
10/10/2017
20:07
Orderly?......Nasdaq up on big volume.Equivalent close on current xrates is £14-32
steeplejack
09/10/2017
08:18
CEO's retirement looks orderly. No need for a panic attack.
broadwood
04/10/2017
13:26
High volume today
samdb
09/9/2017
23:08
About time we had another bid story run riot in the press.
its the oxman
27/7/2017
10:02
Smith & Nephew (SN.), the medical equipment manufacturing company, reported revenue of $1,194m for the second quarter, which was flat on a reported basis and up 3% when foreign exchange headwinds and the gynaecology division disposal are excluded. The company saw a recovery in emerging markets, with revenue up 13% in the quarter. For the first half, the operating profit was $414m, up from $357m the previous year. The trading profit margin was 30 basis points higher at 21.1%, in line with guidance. The group said it continues to expect underlying revenue growth of 3-4% and a 20-70bps improvement in trading profit margin for the full year
broadwood
25/5/2017
09:06
New all time highs on an almost daily basis. And not a whisper in the press ...
mamcw
05/5/2017
08:35
Smith & Nephew said its full year outlook for underlying revenue growth remained unchanged in the 3%-4% range after posting flat first quarter revenue of $1.14bn, flat on a reported basis after -2% impact from the disposal of its gynaecology business and -1% currency headwind. Revenue was up 3% on an underlying basis for the period. Established markets, the US and other established markets revenue were all up 1%. "In Europe we are making progress improving our execution, although the slight headwinds seen last year in some European countries continued,"Smith & Nephew said. "Performance in the emerging markets was good, returning to double-digit growth, with China growing 14% in the quarter." "On a reported basis, we expect 2017 revenue growth to be in the range of 1.6%-2.6% based on prevailing exchange rates at the end of April and reflecting the 80bps headwind from the disposal of the gynaecology business," the company said.
broadwood
05/5/2017
06:26
Live bid candidate. - Smith & Nephew said its Q1 2017 trading was in line with its expectations, and that it was on track to deliver 3-4% underlying revenue growth for the FY. CEO Olivier Bohuon said that in particular the company's performance in the Emerging Markets was good, returning to double-digit growth, with China up 14% underlying. "Our innovative new products, such as the Lens camera and Werewolf Coblation systems, have been well received, and we look forward to the imminent full market release of the Total Knee Application on our Navio robotics-assisted surgery system," said Bohuon. "Over the last few years we have successfully put in place the right structures and capabilities to make the Group stronger, simpler, more agile and efficient. "We continue to focus on execution and expect to see progress through the year." Meantime, for Q1, revenue of $1.142bn was flat on a reported basis after -2% impact from Gynaecology disposal and -1% currency headwind. It was up 3% on an underlying basis. "Smith & Nephew is on-track to deliver 3-4% underlying revenue growth for full year," it said.
broadwood
10/3/2017
09:49
Now Akzo Nobel falls under the global consolidation hammer. Only a matter of time before SN is bought
mamcw
21/2/2017
15:42
Unilever situation underlines attractiveness of UK-based companies whose earnings are global to US predators.
mamcw
09/2/2017
18:58
Nice come back today. Forming a long lower wick to daily candle.
corlis
09/2/2017
17:51
sharp dip at the open but regained nearly all losses to close at 1198. it appears that someone is very keen to accumulate loose stock.
accipitridae
09/2/2017
09:37
dont forget results reflect a period when the CEO took time out for illness and also lost his CFO. SN generates loads of cash and margins are going up now.
accipitridae
09/2/2017
08:38
And down we go on a pretty lacklustre set of results.Doesn't look like we're going to see a marked acceleration in growth in 2017 given a forecast of revenue growth of around 2% and margins,whilst improving,being subject to various "headwinds"."Stryke(r) while the iron's hot" as they say and if they are to rebid,now is a opportune time when the dollar is strong and S&N have undertaken a lot of remedial action.For now,bid expectations will restrict the downside.Along with Astra Zeneca,S&N remains a slow burning fuse that has still to convince the market of its ability to resume a much improved and sustainable growth pattern.I can't help thinking though that global demographics dictates that this company must be very attractive to predators.So,I remain a strong holder.Either they get their act together or get taken over.
steeplejack
08/2/2017
22:07
ok i buy any dips
accipitridae
08/2/2017
10:56
Accipitidae sorry i meant for a LONG
corlis
08/2/2017
08:52
exactly 1200 - what does this mean
accipitridae
06/2/2017
09:24
Chart wise this at 1,200 is starting to show some promise.
corlis
01/2/2017
12:32
This looks like a fairly straightforward f/x play - with so much of S&N's sales worldwide, yet a stock market valuation that in US Dollar terms has fallen sharply, it becomes very affordable to a US based purchaser.
mamcw
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
ADVFN Advertorial
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201205 10:17:28